Apellis Pharmaceuticals, Inc. (APLS)
May 14, 2026 - APLS was delisted (reason: acquired by BIIB)
41.03
-0.03 (-0.07%)
Inactive · Last trade price on May 13, 2026
Apellis Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 405.21 | 466.23 | 411.29 | 351.19 | 551.8 | 640.19 |
Short-Term Investments | - | - | - | - | - | 60.36 |
Cash & Short-Term Investments | 405.21 | 466.23 | 411.29 | 351.19 | 551.8 | 700.55 |
Cash Growth | 13.06% | 13.36% | 17.11% | -36.36% | -21.23% | -20.18% |
Accounts Receivable | 440.3 | 366.22 | 264.93 | 206.44 | 7.73 | 10.1 |
Inventory | 131.41 | 142.56 | 81.4 | 146.36 | 85.71 | 16.29 |
Other Current Assets | 51.11 | 39.83 | 31.33 | 62.34 | 74.28 | 97.11 |
Total Current Assets | 1,028 | 1,015 | 788.95 | 766.33 | 719.52 | 824.05 |
Net Property, Plant & Equipment | 20.36 | 19.9 | 19.04 | 21.09 | 24.9 | 26.08 |
Other Long-Term Assets | 34.15 | 40.51 | 77.06 | 1.31 | 15.8 | 31.64 |
Total Assets | 1,083 | 1,075 | 885.05 | 788.73 | 760.22 | 881.77 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 49.05 | 56.8 | 38.57 | 37.52 | 37.34 | 16.91 |
Accrued Expenses | 133.69 | 166.05 | 140.18 | 127.81 | 95.14 | 103.24 |
Current Portion of Leases | 6.96 | 7.09 | 6.75 | 6.44 | 5.63 | 4.12 |
Other Current Liabilities | 93.74 | 93.66 | - | 75.83 | 29.5 | 7.58 |
Total Current Liabilities | 283.45 | 323.6 | 185.51 | 247.59 | 167.61 | 131.85 |
Long-Term Debt | - | - | 93.34 | 93.03 | 92.74 | 189.02 |
Long-Term Leases | 12.81 | 11.95 | 10.2 | 11.45 | 14.35 | 17.08 |
Other Long-Term Liabilities | 371.35 | 369.57 | 367.46 | 242.13 | 315.65 | 345.15 |
Total Long-Term Liabilities | 384.16 | 381.51 | 471 | 346.62 | 422.74 | 551.26 |
Total Liabilities | 667.61 | 705.11 | 656.51 | 594.21 | 590.35 | 683.1 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0 | 0.01 | 0.01 |
Additional Paid-in Capital | 3,412 | 3,385 | 3,267 | 3,036 | 2,480 | 1,857 |
Accumulated Other Comprehensive Income | -2.41 | -2.1 | -3.31 | -3.54 | -0.88 | -2.09 |
Retained Earnings | -2,994 | -3,013 | -3,035 | -2,837 | -2,309 | -1,657 |
Shareholders' Equity | 414.92 | 370.15 | 228.54 | 194.52 | 169.87 | 198.66 |
Total Liabilities & Equity | 1,083 | 1,075 | 885.05 | 788.73 | 760.22 | 881.77 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 19.77 | 19.03 | 110.3 | 110.93 | 112.71 | 210.22 |
Net Cash (Debt) | 385.44 | 447.2 | 301 | 240.26 | 439.09 | 490.33 |
Net Cash Growth | - | 48.57% | 25.28% | -45.28% | -10.45% | -1.92% |
Net Cash Per Share | 2.98 | 3.44 | 2.43 | 2.02 | 4.14 | 5.81 |
Book Value | 414.92 | 370.15 | 228.54 | 194.52 | 169.87 | 198.66 |
Book Value Per Share | 3.20 | 2.85 | 1.84 | 1.64 | 1.60 | 2.35 |
Tangible Book Value | 414.92 | 370.15 | 228.54 | 194.52 | 169.87 | 198.66 |
Tangible Book Value Per Share | 3.20 | 2.85 | 1.84 | 1.64 | 1.60 | 2.35 |